FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3182639744> ?p ?o ?g. }

• W3182639744 abstract "Abstract Background Rare neuromuscular diseases such as spinal muscular atrophy, spinal bulbar muscular atrophy, muscular dystrophy, Charcot-Marie-Tooth disease, distal myopathy, sporadic inclusion body myositis, congenital myopathy, and amyotrophic lateral sclerosis lead to incurable amyotrophy and consequent loss of ambulation. Thus far, no therapeutic approaches have been successful in recovering the ambulatory ability. Thus, the aim of this trial was to evaluate the efficacy and safety of cybernic treatment with a wearable cyborg Hybrid Assistive Limb (HAL, Lower Limb Type) in improving the ambulatory function in those patients. Results We conducted an open-label, randomised, controlled crossover trial to test HAL at nine hospitals between March 6, 2013 and August 8, 2014. Eligible patients were older than 18 years and had a diagnosis of neuromuscular disease as specified above. They were unable to walk for 10 m independently and had neither respiratory failure nor rapid deterioration in gait. The primary endpoint was the distance passed during a two-minute walk test (2MWT). The secondary endpoints were walking speed, cadence, and step length during the 10-m walk test (10MWT), muscle strength by manual muscle testing (MMT), and a series of functional measures. Adverse events and failures/problems/errors with HAL were also evaluated. Thirty patients were randomly assigned to groups A or B, with each group of 15 receiving both treatments in a crossover design. The efficacy of a 40-min walking program performed nine times was compared between HAL plus a hoist and a hoist only. The final analysis included 13 and 11 patients in groups A and B, respectively. Cybernic treatment with HAL resulted in a 10.066% significantly improved distance in 2MWT (95% confidence interval, 0.667–19.464; p = 0.0369) compared with the hoist only treatment. Among the secondary endpoints, the total scores of MMT and cadence at 10MWT were the only ones that showed significant improvement. The only adverse effects were slight to mild myalgia, back pain, and contact skin troubles, which were easily remedied. Conclusions HAL is a new treatment device for walking exercise, proven to be more effective than the conventional method in patients with incurable neuromuscular diseases. Trial registration : JMACTR, JMA-IIA00156" @default.
• W3182639744 created "2021-07-19" @default.
• W3182639744 creator A5000297625 @default.
• W3182639744 creator A5006308493 @default.
• W3182639744 creator A5015002787 @default.
• W3182639744 creator A5017358609 @default.
• W3182639744 creator A5029327339 @default.
• W3182639744 creator A5034746527 @default.
• W3182639744 creator A5039658736 @default.
• W3182639744 creator A5041881439 @default.
• W3182639744 creator A5044131211 @default.
• W3182639744 creator A5045719343 @default.
• W3182639744 creator A5045760636 @default.
• W3182639744 creator A5048873944 @default.
• W3182639744 creator A5049835634 @default.
• W3182639744 creator A5055051416 @default.
• W3182639744 creator A5055558988 @default.
• W3182639744 creator A5055620250 @default.
• W3182639744 creator A5056194672 @default.
• W3182639744 creator A5056748506 @default.
• W3182639744 creator A5068323449 @default.
• W3182639744 creator A5071912223 @default.
• W3182639744 creator A5072842761 @default.
• W3182639744 creator A5073117349 @default.
• W3182639744 creator A5075135713 @default.
• W3182639744 creator A5077862315 @default.
• W3182639744 creator A5082179463 @default.
• W3182639744 creator A5082414399 @default.
• W3182639744 creator A5087796335 @default.
• W3182639744 creator A5089998921 @default.
• W3182639744 creator A5091302347 @default.
• W3182639744 date "2021-07-07" @default.
• W3182639744 modified "2023-09-30" @default.
• W3182639744 title "Cybernic treatment with wearable cyborg Hybrid Assistive Limb (HAL) improves ambulatory function in patients with slowly progressive rare neuromuscular diseases: a multicentre, randomised, controlled crossover trial for efficacy and safety (NCY-3001)" @default.
• W3182639744 cites W1956237300 @default.
• W3182639744 cites W1968201376 @default.
• W3182639744 cites W1990038185 @default.
• W3182639744 cites W1999778124 @default.
• W3182639744 cites W2000424576 @default.
• W3182639744 cites W2002535840 @default.
• W3182639744 cites W2005337385 @default.
• W3182639744 cites W2010239598 @default.
• W3182639744 cites W2014145468 @default.
• W3182639744 cites W2082414435 @default.
• W3182639744 cites W2086884126 @default.
• W3182639744 cites W2090656762 @default.
• W3182639744 cites W2093049872 @default.
• W3182639744 cites W2097024559 @default.
• W3182639744 cites W2143759122 @default.
• W3182639744 cites W2154393469 @default.
• W3182639744 cites W2231489206 @default.
• W3182639744 cites W2306612028 @default.
• W3182639744 cites W2593956993 @default.
• W3182639744 cites W2772449942 @default.
• W3182639744 cites W2775386989 @default.
• W3182639744 cites W2789114047 @default.
• W3182639744 cites W2922439241 @default.
• W3182639744 cites W2932986502 @default.
• W3182639744 cites W2960397495 @default.
• W3182639744 cites W2962777035 @default.
• W3182639744 cites W2991525661 @default.
• W3182639744 cites W2996132696 @default.
• W3182639744 cites W3028323243 @default.
• W3182639744 cites W4213250783 @default.
• W3182639744 cites W4233334050 @default.
• W3182639744 cites W561101863 @default.
• W3182639744 doi "https://doi.org/10.1186/s13023-021-01928-9" @default.
• W3182639744 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8261928" @default.
• W3182639744 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34233722" @default.
• W3182639744 hasPublicationYear "2021" @default.
• W3182639744 type Work @default.
• W3182639744 sameAs 3182639744 @default.
• W3182639744 citedByCount "20" @default.
• W3182639744 countsByYear W31826397442021 @default.
• W3182639744 countsByYear W31826397442022 @default.
• W3182639744 countsByYear W31826397442023 @default.
• W3182639744 crossrefType "journal-article" @default.
• W3182639744 hasAuthorship W3182639744A5000297625 @default.
• W3182639744 hasAuthorship W3182639744A5006308493 @default.
• W3182639744 hasAuthorship W3182639744A5015002787 @default.
• W3182639744 hasAuthorship W3182639744A5017358609 @default.
• W3182639744 hasAuthorship W3182639744A5029327339 @default.
• W3182639744 hasAuthorship W3182639744A5034746527 @default.
• W3182639744 hasAuthorship W3182639744A5039658736 @default.
• W3182639744 hasAuthorship W3182639744A5041881439 @default.
• W3182639744 hasAuthorship W3182639744A5044131211 @default.
• W3182639744 hasAuthorship W3182639744A5045719343 @default.
• W3182639744 hasAuthorship W3182639744A5045760636 @default.
• W3182639744 hasAuthorship W3182639744A5048873944 @default.
• W3182639744 hasAuthorship W3182639744A5049835634 @default.
• W3182639744 hasAuthorship W3182639744A5055051416 @default.
• W3182639744 hasAuthorship W3182639744A5055558988 @default.
• W3182639744 hasAuthorship W3182639744A5055620250 @default.
• W3182639744 hasAuthorship W3182639744A5056194672 @default.
• W3182639744 hasAuthorship W3182639744A5056748506 @default.
• W3182639744 hasAuthorship W3182639744A5068323449 @default.
• W3182639744 hasAuthorship W3182639744A5071912223 @default.
• W3182639744 hasAuthorship W3182639744A5072842761 @default.
• W3182639744 hasAuthorship W3182639744A5073117349 @default.
• W3182639744 hasAuthorship W3182639744A5075135713 @default.

• next